Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | ESR1 | P03372 | 6/20 | 0.47 |
| ▸ | ESR2 | Q92731 | 6/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 2/20 | 0.41 |
| ▸ | MAOA | P21397 | 2/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.39 |
| ▸ | TTR | P02766 | 1/20 | 0.39 |
| ▸ | EDNRB | P24530 | 1/20 | 0.37 |
| ▸ | EDNRA | P25101 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18898168 | 1.00 | MEN1 (0.49) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL30362919 | 1.00 | MEN1 (0.49) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL2719223 | 1.00 | MEN1 (0.49) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL15312297 | 1.00 | MEN1 (0.49) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL26946056 | 0.89 | MEN1 (0.51) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL19655436 | 0.88 | ESR1 (0.47) | ESR1ESR2CYP3A4MAOAMAOB | |
| SCHEMBL10098033 | 0.87 | ESR1 (0.46) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL15954349 | 0.87 | ESR1 (0.46) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL30362821 | 0.87 | ESR1 (0.46) | MEN1KMT2AESR1ESR2CYP3A4 | |
| SCHEMBL2717911 | 0.87 | ESR1 (0.46) | MEN1KMT2AESR1ESR2CYP3A4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 28 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2023-11-23 | — | — | US | disclosed |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-08-15 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230233519-A1 | COMBINATION THERAPIES | Aardvark Therapeutics, Inc. | 2023-07-27 | — | — | US | disclosed |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MEI PHARMA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MEI PHARMA, INC. | 2023-05-11 | — | — | US | disclosed |
| US-11583514-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2023-02-21 | — | — | US | disclosed |
| US-20210361614-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | Aardvark Therapeutics, Inc. | 2021-11-25 | — | — | US | disclosed |
| US-9708283-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9708283-B2 | Isoflavonoid compositions and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-07-18 | — | — | US | disclosed |
| US-9663484-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-9663484-B2 | Isoflavonoid compounds and methods for the treatment of cancer | MEI PHARMA, INC. (US) | 2017-05-30 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2014-08-21 | — | — | US | disclosed |
| US-20130273177-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| US-20130273177-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2013-10-17 | — | — | US | disclosed |
| WO-2012061413-A2 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
| WO-2012061409-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | MARSHALL EDWARDS, INC. (US) | 2012-05-10 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230145478-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | MEN1 4218/4885KMT2A 3410/4885ESR1 57/4885 |
| US-11723893-B2 | Isoflavonoid compositions and methods for the treatment of cancer | BAX, CASP3, SI | MEN1 4303/4885KMT2A 4470/4885ESR1 176/4885 |
| US-20130273177-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | MEN1 4303/4885KMT2A 4470/4885ESR1 176/4885 |
| US-20230233519-A1 | COMBINATION THERAPIES | BCL2, BAK1, BCL2L2 | MEN1 3319/4885KMT2A 1485/4885ESR1 3784/4885 |
| US-20210361614-A1 | ISOFLAVONOID COMPOSITIONS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, SI | MEN1 4303/4885KMT2A 4470/4885ESR1 176/4885 |
| US-11583514-B2 | Isoflavonoid compounds and methods for the treatment of cancer | BAX, CASP3, API5 | MEN1 4218/4885KMT2A 3410/4885ESR1 57/4885 |
| US-20140234295-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | MEN1 4218/4885KMT2A 3410/4885ESR1 57/4885 |
| US-20230372287-A1 | ISOFLAVONOID COMPOUNDS AND METHODS FOR THE TREATMENT OF CANCER | BAX, CASP3, API5 | MEN1 4218/4885KMT2A 3410/4885ESR1 57/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.